Dual Affinity to RBCs and Target Cells (DART) Enhances Both Organ- and Cell Type-Targeting of Intravascular Nanocarriers
Laura T. Ferguson(Pulmonary and Allergy Associates), Jeremy Katzen(Translational Therapeutics (United States)), Edward Cantu(Hospital of the University of Pennsylvania), Tea Shuvaeva(Translational Therapeutics (United States)), Vladimir R. Muzykantov(Translational Therapeutics (United States)), Vladimir V. Shuvaev(California University of Pennsylvania), Xiaonan Ma(Translational Therapeutics (United States)), Carlos H. Villa(Center for Biologics Evaluation and Research), Maria C. Basil(Boston University), Edward E. Morrisey(Penn Center for AIDS Research), Jacob W. Myerson(Translational Therapeutics (United States)), Jia Nong(University of Pennsylvania), Oscar A. Marcos‐Contreras(University of Pennsylvania), Samir Mitragotri(Massachusetts Institute of Technology), Jichuan Wu(University of Pennsylvania), Elizabeth D. Hood(Translational Therapeutics (United States)), Zhicheng Wang(Translational Therapeutics (United States)), Justine Carl(University of Pennsylvania)
Cited by 56
Related Papers
Nanoparticles in the clinic
|Bioengineering & Translational Medicine|2016|1.2k
A Reversibly Switching Surface
|Science|2003|1.1k
Specialized pro-resolving mediators: endogenous regulators of infection and inflammation
|Nature reviews. Immunology|2015|758
Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation
|American Journal of Respiratory and Critical Care Medicine|2013|686